Nasdaq

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) ...
ascopubs.org

Personalised artificial intelligence–based approach to assessing objective response to immunotherapy in patients with solid tumors.

Performance assessment of an algorithm-based decision-making platform for patient prioritization during cancer care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Nasdaq

Cardiff Oncology Reports 40% Objective Response Rate in Phase 1b Trial of Onvansertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer

Phase 1b trial shows 40% response rate for onvansertib plus paclitaxel in metastatic triple-negative breast cancer, with manageable toxicity. Cardiff Oncology, Inc. announced promising results from a ...
MedPage Today

New Drug Effective for Tenosynovial Giant Cell Tumors, and With No Liver Concerns

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- An ...